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Abstract The metabo-ring initiative brought together five
nuclear magnetic resonance instruments (NMR) and 11
different mass spectrometers with the objective of assessing
the reliability of untargeted metabolomics approaches in
obtaining comparable metabolomics profiles. This was
estimated by measuring the proportion of common spectral
information extracted from the different LCMS and NMR
platforms. Biological samples obtained from 2 different
conditions were analysed by the partners using their own in-
house protocols. Test #1 examined urine samples from adult
volunteers either spiked or not spiked with 32 metabolite
standards. Test #2 involved a low biological contrast situ-
ation comparing the plasma of rats fed a diet either sup-
plemented or not with vitamin D. The spectral information
from each instrument was assembled into separate statisti-
cal blocks. Correlations between blocks (e.g., instruments)
were examined (RV coefficients) along with the structure of
the common spectral information (common components
and specific weights analysis). In addition, in Test #1, an
outlier individual was blindly introduced, and its identifi-
cation by the various platforms was evaluated. Despite large
differences in the number of spectral features produced after
post-processing and the heterogeneity of the analytical
conditions and the data treatment, the spectral information
both within (NMR and LCMS) and across methods (NMR
vs. LCMS) was highly convergent (from 64 to 91 % on
average). No effect of the LCMS instrumentation (TOF,
QTOF, LTQ-Orbitrap) was noted. The outlier individual
was best detected and characterised by LCMS instruments.
In conclusion, untargeted metabolomics analyses report
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consistent information within and across instruments of
various technologies, even without prior standardisation.
Keywords Inter-laboratory  Untargeted metabolomics 
Mass spectrometry  Nuclear magnetic resonance 
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1 Introduction
Metabolomics has become essential to understanding the
impact of external or pathological stressors on a biological
system (Ryan and Robards 2006). Although early attempts at
using such analytical approaches took place in the 1970s
(Pauling et al. 1971), metabolomics approaches have
increased only since the beginning of this century and have
appeared promising only during the present decade (Opinion
2010). For instance, recent studies have transitioned meta-
bolomics from proof-of-principle to validation. In these
studies, untargeted metabolomics allowed a hypothesis to be
generated and to be challenged in order to validate new
biomarkers of disease (Wang et al. 2011; Cobb et al. 2013),
which ultimately led to the development of a clinical test
(Cobb et al. 2013). However, the implementation of meta-
bolomics is not trivial and requires validation and an esti-
mation of reliability, even though some standardisation
attempts have been made and recommendations have been
proposed (Fiehn et al. 2006; Lindon et al. 2005; Scalbert et al.
2009). This is an important issue because, in addition to
sampling (Griffin et al. 2007) and extraction procedures
(Want et al. 2006; Tulipani et al. 2012; Pereira et al. 2010),
the performance of metabolomics analyses also relies on the
instrument type (Gika et al. 2010; Williams et al. 2005;
Rubtsov et al. 2007) and on the methods implemented (van
den Berg et al. 2006; Tautenhahn et al. 2008; Sumner et al.
2007). Such heterogeneity can thus result in discrepancies in
the results produced from different places and prevent their
generalisation. Several inter-laboratory studies have
attempted to validate the accuracy of the metabolomics
approach, but these studies all used similar instruments,
either NMR of different magnetic fields (Viant et al. 2009;
Ward et al. 2010) or GC–MS (Allwood et al. 2009) and LC–
MS (Benton et al. 2012) of the same type. When using tight
standardized conditions among the partners these studies
showed a high degree of inter-laboratory repeatability.
However they did not address comparisons of heterogeneous
instruments or methods nor the fact that strict protocol
designs are difficult to extrapolate to real-life situations.
Comparisons among various instruments can also be chal-
lenging because metabolite coverage is highly instrument-
dependent (Mandal et al. 2012; Suhre et al. 2010). The best
starting point and limiting point in the metabolomics ana-
lytical workflow is to compare the spectral information
gathered from instruments of various technologies irre-
spective of the samples preparation step. This issue was
recently addressed at the intra-laboratory scale using two
types of LCMS systems of different technologies (Gika et al.
2010; Glauser et al. 2013). The authors found good conver-
gence between the instruments, but the results of these
intra-laboratory studies needs to be challenged at the
A. Verdu
BRUKER, 4 alle´e Hendrick Lorentz,
77447 Marne La Valle´e Cedex 2, France
B. Lyan  C. Migne´  C. Manach  E. Pujos-Guillot 
F. Giacomoni  J.-F. Martin
INRA, UMR 1019, UNH, CRNH Auvergne,
63000 Clermond-Ferrand, France
B. Lyan  C. Migne´  C. Manach  E. Pujos-Guillot 
F. Giacomoni  J.-F. Martin
INRA, UMR 1019, Plateforme d’Exploration du Me´tabolisme,
UNH, 63000 Clermond-Ferrand, France
C. Canlet
INRA, UMR 1331 TOXALIM (Research Center in Food
Toxicology), Axiom-Metatoul, 31027 Toulouse, France
C. Junot
Laboratoire d’Etude du Me´tabolisme des Me´dicaments,
DSV/iBiTec-S/SPI, CEA-Saclay, 91191 Gif-sur-Yvette Cedex,
France
C. Guillou  H. Chassaigne  M. Bossis
European Commission, Joint Research Centre, Institute for
Health and Consumer Protection, Via Enrico Fermi 2749,
21027 Ispra, Italy
D. Jabob
INRA, UMR1332 Fruit Biology and Pathology, Centre INRA de
Bordeaux, 33140 Villenave d’Ornon, France
D. J.-R. Bouveresse  E. Paris  D. N. Rutledge
INRA, UMR 1145 Inge´nierie Proce´de´s Aliments, 75005 Paris,
France
D. J.-R. Bouveresse  E. Paris  D. N. Rutledge
AgroParisTech, UMR 1145 Inge´nierie Proce´de´s Aliments,
75005 Paris, France
F. Jourdan
INRA, UMR 1331 TOXALIM (Research Center in Food
Toxicology), Metabolism of Xenobiotics (MeX),
31027 Toulouse, France
F. Courant  J.-P. Antignac
LUNAM Universite´, Oniris, Laboratoire d’Etude des Re´sidus et
Contaminants dans les Aliments (LABERCA), USC INRA 1329,
BP 50707, 44307 Nantes Cedex 3, France
G. Le Gall  M. Defernez  M. Philo
Institute of Food Research, Norwich Research Park,
Norwich NR4 7UA, UK
808 J.-C. Martin et al.
123
inter-laboratory scale and to be extended to heterogenous
instruments to allow complete generalisation.
Thus, to respond to this challenge and to facilitate stan-
dardisation initiatives, it would be wise to determine the
usefulness of the current metabolomics strategies in deliv-
ering homogeneous results using both homologous and
heterologous instrumentation and methods. To this end, we
designed 2 metabolomics ring-tests (Test #1 and Test #2), in
which the same sets of samples were analysed without any
imposed standardisation on 16 instruments (5 NMR and 11
LCMS) located in three European countries. These two tests
included a spiking experiment in human urines and plasma
analysis of rats challenged with vitamin D. Our primary goal
was not to make comparisons at the analytes level but rather
to evaluate the inter-instrument convergence at the meta-
bolic profiling level. A specific statistical design was applied
to make these comparisons possible. Both instruments
(NMR and LCMS) and procedures used covered the most
common situations observed in non-targeted metabolomics.
2 Materials and methods
2.1 Experimental setup
2.1.1 Test #1: High biological contrast
Fourteen volunteers were recruited, including 13 males
(age 17–50) and one woman in mid-pregnancy (age 32).
The study was approved by the regional committee on
human experimentation (No. 2008-A01354–51, Comite´ de
Protection des Personnes Sud Me´diterrane´e I). A written
informed consent for the use of the urine samples was
signed by each individual. The sample list was sent blind to
all analytical partners.
The specific gravities of the urine samples were deter-
mined using a density meter (Anton Paar, Austria) to cal-
culate a normalisation factor to be applied to each signal
intensity measured by NMR or LCMS (Cone et al. 2009)
whenever specified.
A mixture of standards was prepared to be incorporated
into the urine samples using the NuGO standard operating
procedure (SOP) number 43 produced by the University of
Copenhagen, details of which are available via the web link:
http://www.nugo.org/frames.asp?actionID=39148&action=
loginFromPP. For further information, please contact Lars
Dragsted ldra@life.ku.dk. The standard mixture only con-
tained 32 chemicals (see online resource Table 1): ascorbic
acid, citrulline, creatinine, taurine, uric acid, caffeine, glu-
taric acid, inosine, isoleucine, leucine, pyroglutamic acid,
methionine, methylmalonic acid, N-methylhistidine, ami-
nobenzoic acid, phenylalanine, proline, riboflavin, adeno-
sine, adenine, adipic acid, azelaic acid, caffeic acid,
tryptophan, tyrosine, uracil, uridine, chenodeoxycholic acid,
cholic acid, cortisone, deoxycholic acid, glycocholic acid.
All the molecules can be naturally present in urine, except
chenodeoxycholic acid.
To prevent dilution the standard mixture was aliquoted
then lyophilised and reconstituted with each urine sample.
2.1.2 Test #2: low biological contrast
Vitamin D is involved in many biological functions and in
the maintenance of health (Adams and Hewison 2010). It
occurs endogenously but can also be provided by various
food sources. We chose to examine its metabolic effect as a
test of a low biological contrast study, which is a common
situation in nutritional metabolomics research. Twenty
Sprague–Dawley male rats, weighing 250 g and purchased
from JANVIER SAS (Le Genest Saint Ile, France), were
fed for 6 weeks after 1 week of acclimatisation while
maintained in a dark/light cycle of 12 h. All experiments
were conducted according to the French Regulations for
Animal Experimentation (Art 19. Oct 1987, Ministry of
Agriculture) and in conformity with the Public Health
Service Policy after approval by our institutional Animal
Care and Use Committee. Half of the rats were fed with the
low vitamin D diet (1,000 IU/kg of diet, SIGMA ref
C9756, L’Isle d’Abeau Chesnes, France), while the others
received a high vitamin D diet (20,000 IU/kg of diet)
(online resource Table 2), as described elsewhere (Fleet
et al. 2008). After 6 weeks, the rats were anesthetised with
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isoflurane and exsanguinated through the left ventricle with
a heparinised syringe. The blood was immediately cooled
to 0 C, and the plasma separated at 3,000 g and 4 C for
10 min. For LCMS analysis, plasma deproteinisation and
metabolite extraction were performed by methanol treat-
ment, as described by (Pereira et al. 2010); 500 lL plasma
samples were kept unprocessed for NMR analysis. All the
operations were performed on randomly ordered samples.
We checked that the supplementation increased the vitamin
D in the plasma by assaying the 25(OH)-vitamin D3 con-
centration. As a result of the supplementation, the rats
weighed more after 6 weeks (552 ± 9 g versus 517 ± 5 g
in the supplemented versus deprived rats, respectively;
P\ 0.05) and the 25(OH)-vitamin D3 concentration was
significantly increased (215 ± 8 and 63 ± 8 mmol/L in
supplemented vs deprived rats, respectively). Extracted
(for LCMS) or unprocessed (for NMR) plasma samples
were aliquoted into Eppendorf tubes and shipped to par-
ticipants in dry ice along with QC samples and blank
samples. Once received, the samples were stored at
-80 C until analysis within 1–3 months.
2.2 Metabolomics analysis
The instruments used in both tests were, for NMR, a
Bruker 500 Avance III, a Bruker DRX-600 Avance, and
three Bruker Avance III 600, and for LCMS (all operating
in ESI), a Bruker microTOFQ coupled to an Agilent
RRLC, a Bruker microTOFQII coupled to an Ultimate
3000 Dionex U-LC, a Bruker QTOF Maxis Impact coupled
to an Ultimate 3000 Dionex U-LC, a Waters QTOF Pre-
mier coupled to an Acquity UPLC, a Waters QTOF Micro
coupled to an Acquity UPLC, a Thermo Fisher Scientific
LTQ-Orbitrap coupled to an Agilent 1200 RRLC, a
Thermo Fisher Scientific LTQ-Orbitrap Discovery coupled
to an Ultimate 3000 Dionex U-LC, a Thermo Fisher Sci-
entific LTQ-Orbitrap Discovery coupled to an Accela
liquid chromatographic system (Thermo Fisher Scientific,
Les Ulis, France), a Thermo Fisher Exactive coupled to a
Shimadzu Nexera liquid chromatography system, a Waters
QTOF Synapt-2 MS coupled to a ThermoAccela binary
UPLC, and a Bruker Micro-TOF delivered by an Agilent
1100 LC.
For both NMR and LCMS analyses, each participating
laboratory was asked to use its own in-house protocols for
instrument tuning, data processing and post-processing. A
detailed description of all the procedures used by the dif-
ferent platforms is given in the online resource. Analyses
were performed in random order (LCMS and NMR). The
same quality control sample, consisting of a pool of urine
(Test #1) or plasma (Test #2) samples, was provided to
each partner and was analysed by insertion into the
analytical series (from every 5 to every 10 samples) to
check the performance of the analytical system in terms of
retention times, accurate mass measurements, and signal
intensities (all LCMS). The analytical variability compared
to the biological variability was assessed using these
quality controls samples. The low dispersion (almost nill
with NMR) of the QC samples obtained by each partner
after PC analysis indicated proper analytical conditions.
2.3 Statistical analysis
The statistical analyses were applied separately for Test #1
and Test #2. The Test #1 samples were analysed by 14
instruments (5 NMR and 9 LCMS operating in positive and
negative modes), whereas in Test #2, 12 instruments (4
NMR and 8 LCMS operating mainly in positive mode)
were used (Table 1).
A workflow of the statistical design is presented in the
online resource Figure 1.
For each test data from all the platforms were pooled,
and one statistical analysis each was applied. The aim of
this global statistical analysis was to assess the conver-
gence of the biological information delivered by the met-
abolic profiling and provided by several instruments (NMR
and LC–MS). All statistical methods used to extract the
common information shared by all the platforms are
detailed in the online resource. Briefly, we compared the
relationship between the data tables using RV coefficients
(Escoufier 1973; Lavit et al. 1994), which can be inter-
preted as the multivariate equivalent of a squared corre-
lation coefficient (R2) ranging from [0–1]. An RV
coefficient equal to 1, when considering the two tables X
and Y, means that the relative position of the samples in X
is similar to those in Y. In other words, the information
included in the two data tables is identical. We also
explored the common information among the various data
tables using the Common components and specific weights
analysis (i.e., CCSWA or ComDim). This method was
developed by Qannari et al. in 2000 (Qannari et al. 2000)
for sensory profiling analysis and has also been applied to
chemometrics studies (Mazerolles et al. 2002). Several
extensions of the method have been developed recently
(Amat et al. 2010; Jouan-Rimbaud Bouveresse et al. 2011;
Mazerolles et al. 2006). CCSWA estimates the dispersion
of the samples in a series of dimensions that are common
to all the data tables. Each data Table has a specific weight
(called salience) that quantifies its contribution to each
common dimension. Based on global scores, samples can
be projected onto the common space to determine the
sample structures that are common to all data tables. The
CCSWA algorithm has been described elsewhere (Bro
et al. 2008; Qannari et al. 2000).
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The RV coefficient matrices and CCSWA were com-
puted using the SAISIR package developed for the open
source SCILAB software (Bertrand and Cordella 2008).
Our secondary endpoint was to identify a set of features
allowing discrimination of the two groups in each test. For
Test #1, the additional objective for all partners was to
identify all of the 32 molecules added to the spiked sam-
ples. Table 1 summarises the statistical methods used by
each laboratory for identifying the discriminating features
in both tests. The univariate statistics refer to the signifi-
cance of the fold-change, whereas the multivariate meth-
odology refers to the PLS-DA regression. The
discriminating features found by each partner were also
compared to the ones found in the CCSWA performed on
the post-processing datasets computed in the data collec-
tion centre.
2.3.1 Correlation networks
The correlation network is an efficient tool for providing a
graphical representation of the correlations between vari-
ables. In this study, the correlation network visualises
multiple proximities between instruments based on the
estimated RV coefficients. The RV coefficient networks
were calculated and visualised using the Cytoscape soft-
ware (Shannon et al. 2003) (http://www.cytoscape.org/).
2.4 Characterisation of the Test #1 outlier
The CCSWA performed in the data collection centre was
applied to select spectral features present in the NMR and
LCMS analyses that discriminated the blind biological
outlier individual introduced among the urine samples. For
annotation purposes, the features retained were selected
according to a correlation value, with the common com-
ponent characterising the outlier as being more than 0.8 for
LCMS or more than two z-scores for NMR. This biological
outlier was a mid-term pregnant woman contrasting with
the samples collected from male individuals.
2.5 Annotation of discriminating features
Annotation was either performed after operator visual
spectral inspection or using automated procedures based on
accurate mass and referencing to public or in-house dat-
abases (MS instruments). Metabolites identification refer-
red to level 1 of the MSI when dealing with the spiked
standards, or to level 2 whenever applicable, and thus
corresponded to putative annotation (Sumner et al. 2007).
Table 1 Descriptions of the
MS and NMR platforms used in
the two tests and the number of
features retained per test and
instrument
a These instruments are located
on the same platform
b This platform used a QTOF
analysis in Test #1 and an
Orbitrap analysis in Test #2
1 N for NMR spectrometer, Q
for QTOF mass spectrometer, O
for orbitrap mass spectrometer,
T for TOF mass spectrometer.
The P or N appended to the
mass spectrometer identifier
number denotes positive or
negative ionisation mode,
respectively
Platform
ID1
Instruments Mode Deconvolution
software
Test #1
n = 25
Test #2
n = 18
Stat
N1 Bruker 600 – AMIX 751 881 Multivariate
N2 Bruker 600 – AMIX 252 – Univariate and
multivariate
N3 Bruker 600 – AMIX 88 9300 Multivariate
N4 Bruker 500 – In-house 9,699 9550 Multivariate
N5a Bruker 600 – AMIX 233 120 Multivariate
O1P LTQ orbitrap Positive XCMS 5,035 710
Q6P/O2Pb QTOF premier/
orbitrap
Positive XCMS 1,922 1295 Univariate
Q6N QTOF premier Negative XCMS 314 – Univariate
O3P LTQ orbitrap Positive XCMS 1,827 1979 Univariate
O3N LTQ orbitrap Negative XCMS 1,715 795 Univariate
O4P LTQ orbitrap Positive XCMS 2,668 – Multivariate
Q1P QTOF micro Positive XCMS 1,181 504 Multivariate
Q1N QTOF micro Negative XCMS 1,288 – Multivariate
Q2P QTOF impact Positive XCMS 1,688 – Multivariate
Q2N QTOF impact Negative XCMS 2,492 – Multivariate
Q3P microQTOF Positive XCMS 908 2631 Univariate
Q4P QTOF micro II Positive XCMS 909 2277 Multivariate
Q4N QTOF micro II Negative XCMS 438 – Multivariate
Q5Pa QTOF synapse Positive XCMS 6,992 1595 Univariate
Q5Na QTOF synapse Negative XCMS 5,167 – Univariate
T1Pa TOF Positive XCMS 580 – Univariate
T1Na TOF Negative XCMS 398 – Univariate
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3 Results
3.1 Sample analysis, data acquisition and post-
processing
The procedures used for data acquisition and data post-
processing and filtering prior to the statistical analyses are
detailed in the online resource.
For NMR, the operators used AMIX or in-house C
programs to bin the spectra into regions of various ppm
widths (from 0.001 to 0.04 ppm).
For LCMS, all partners used XCMS for peak picking
and retention time correction; however, the basal parame-
ters and methods scripts differed among the partners based
on their individual background experience. This led to
different workflows for XCMS from one platform to the
other. In addition, further signal filtering was sometimes
applied, such as de-isotoping and de-adducting, de-noising
using blank samples or QC dilutions, elimination of unre-
liable features based on the use of QC samples, etc. (see
online resource).
As a result, the various non-standardised, in-house
procedures applied to the heterogeneous analytical plat-
forms led to very different datasets in terms of the number
of features retained and the characteristic features for the
two tests (Table 1). For instance, the number of features
varied by 2 orders of magnitude from the lowest to the
highest dimensional data Table (from 88 to 9699 for Test
#1 and from 120 to 9550 for Test #2). The number of
features was less heterogeneous within the LCMS
Table 2 Results of Test #1 for the various platforms
Platform
ID1
Mode Total
features
Discriminating
features from
independent
analysis
Number of
identified
standard
molecules2
Discriminating
features from
CCSWA
(r[ 0.8)
Features
shared by
both
methods
%1 of
shared
features
Discriminating
features from
CCSWA
(r[ 0.9)
Features
shared by
both
methods
%3 of
shared
features
N1 – 751 86 22 188 65 35 103 50 49
N2 – 252 93 24 43 33 77 30 22 73
N3 – 88 36 16 37 23 62 21 13 62
N4 – 9,699 NR 345 – 66
N5a – 233 133 23 110 68 62 60 43 72
O1P Pos 5,035 25 798 – 552
Q6P Pos 1,922 354 22 820 102 12 398 38 9.5
Q6N Neg 314 137 14 69 43 62 27 19 70
O3P Pos 1,827 265 23 194 194 100 158 158 100
O3N Neg 1,715 348 25 222 222 100 177 177 100
O4P Pos 2,668 11 433 – 256
Q1P Pos 1,181 118 21 129 108 84 104 95 91
Q1N Neg 1,288 210 13 171 171 100 152 152 100
Q2P Pos 1,688 440 NR 472 415 88 388 373 96
Q2N Neg 2,492 153 NR 268 149 56 203 143 70
Q3P Pos 908 167 13 184 83 45 144 66 46
Q4P Pos 909 202 23 176 85 48 151 74 49
Q4N Neg 438 74 15 58 58 100 52 52 100
Q5Pa Pos 6,992 2215 20 1431 1430 100 970 970 100
Q5Na Neg 5,167 1137 22 475 474 100 257 257 100
T1Pa Pos 580 192 22 139 139 100 117 117 100
T1Na Neg 398 101 14 77 77 100 66 66 100
Total number of features, number of discriminating features per statistical method and number of discriminating features shared by the two
statistical methods for each instrument
a These instruments are located on the same platform
1 N for NMR spectrometer, Q for QTOF mass spectrometer, O for Orbitrap mass spectrometer, T for TOF mass spectrometer. The P or N
appended to the mass spectrometer identifier number denotes positive or negative ionisation mode, respectively
2 Annotated standard molecules detected by each laboratory are reported in online resource Table 3; annotation was performed only on features
that statistically differed in the spiked samples, except for partners O1, Q2 and N4 (NR for non-reported)
3 The percentage of discriminating features (selected by the CCSWA) that were also selected as discriminating by the simple statistical analysis
carried out by each participating laboratory
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instruments (from 398 to 6992 in Test #1 and from 504 to
2271 in Test #2).
3.2 Group discrimination by statistical analyses
In Test #1 (high contrast), all the platforms used their own
statistical analyses and all partners were able to discrimi-
nate the spiked group from the non-spiked group (Tables 1,
2). The CCSWA performed by the referent partner brought
further external validation of each partner’s findings
(Table 2). Using either ESI–MS approaches and the exact
mass of the monoisotopic ion and isotopic distribution or
one-dimensional ppm shifts (NMR), from 16 to 23 were
identified by NMR, and from 13 to 25 of the 32 spiked
standards were identified by LCMS (both polarity modes)
(see online resource Table 3). From 36 to 133 discrimi-
nating features for NMR and from 74 to 2215 features for
LCMS were thus retained by the partners and characterised
the spiked molecules. The proportions of discriminating
features produced varied from 11 to 57 % in the NMR
instruments and from 5 to 33 % in the LCMS instruments
(from Table 2 data). The CCSWA calculated from the
combination of all the data tables confirmed the partner’s
statistical analyses, with a clear discrimination between the
spiked and non-spiked urine samples found by all platforms
(Fig. 1a and online resource Figure 5A).
Fig. 1 Individual common component and specific weights analysis
scores (a) and saliences or loadings (b) calculated from the Test #1
datasets. The first common component discriminates the control
group from the spiked group. The second common component
describes the inter-individual variability that was most common to all
the instruments. The third and fourth components highlight the
specific metabolic profiles of urine samples 8 and 5, respectively. For
the NMR instruments (NMR1, NMR3 and NMR5), the major part of
the variability (i.e., 70 %) explained the discrimination between the
two groups. NMR instruments characterised 10 % of the total
variability as inter-individual variability (saliences on the second
common component). Among the LCMS instruments, 20 to 50 % of
the total variability explained the inter-group variability (first
component), and 20 to 30 % of the total variability explained the
inter-individual variability. NMR2 was different from the other NMR
instruments because it was associated with, respectively, 35 and 38 %
of the total inter-group and inter-individual variability. Two particular
urine samples (individuals #5 and #8) were identified by all LCMS
instruments, and only NMR2 identified individual #8, in the same
proportion (approximately 5 % of total variability). a Open circles
denote the original urine samples, grey circles denote the matched
spiked samples. b Open diamond denotes NMR, black circles denote
Orbitrap, squares denote QTOF, and triangles denote TOF
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However, the NMR platforms generally performed
better than LCMS in distinguishing the spiked versus non-
spiked urine, with an average percentage variance (CC1
score) of 0.494 ± 0.092 compared to 0.316 ± 0.026 for
LCMS (P = 0.0159) (Fig. 1b). Conversely, the LCMS
platforms showed higher CC scores than did NMR in
depicting interindividual metabotypes (0.285 ± 0.092 and
0.132 ± 0.061 in CC2 for LCMS and NMR, respectively,
P = 0.0093, Fig. 1b). As a result, all the LCMS instru-
ments were equally proficient at distinguishing interindi-
vidual and intergroup variability, whereas NMR mainly
described intergroup variability, except NMR2, which
shared closer characteristics with the LCMS platforms than
with the other NMR instruments. Of note is that the relative
score distribution pattern summarizing the individual me-
tabotypes was not modified in the spiked versus native
urine samples in Test #1 either for NMR or LCMS
(Figs. 1a and 5A).
The urine of a mid-term pregnant woman introduced as
a blind outlier (individual #5) was detected in the common
space component 4 (Fig. 1a), but this occurred mainly with
LCMS (variance described in CC4 was 0.051 ± 0.003 for
LCMS and 0.033 ± 0.006 for NMR, P = 0.0113)
(Fig. 1b). Based on the exact mass only or on the exact
mass and isotopic distribution of the discriminating fea-
tures, most of the LCMS instruments found that the dif-
ference between this individual and the others was due to
estro-progestative components in the urine (online resource
Table 4). On the other hand, NMR found that the dis-
crimination was due to alanine, lactate, glycine, glutamine,
and threonine, among the most consensual metabolites
(online resource Table 4), as determined from chemical
shifts and database matching. Of note is that another outlier
(individual # 8) was unexpectedly revealed in CC3 of
Fig. 1a. It was also detected by most of the LCMS
instruments and by NMR2 (Fig. 1b).
Fig. 2 Individual common component and specific weights analysis
scores (a) and saliences or loadings (b) calculated from the Test #2
datasets. No common dimension discriminated the groups, although
common component #2 showed a trend towards group discrimination.
More than 50 % of the total variability of the NMR instruments and
of 2 LCMS instruments (Q2P and Q6P) was recovered in the first two
common dimensions. The variability of all other LCMS instruments
was mainly in the third and the fourth common components. The
structure of the samples associated with the second common
component is essentially due to the NMR instruments
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In Test #2 (low biological contrast), no discrimination
between the groups was determined based on the signals
detected by each instrument unless specific signal correc-
tion was applied (orthogonalisation to discard part of the
variance that was not linked to class characteristics) (Fearn
2000; Trygg and Vold 2002). The vitamin D specific bio-
logical effect was thus not measured as the major part of
the biological variance. Even if the two groups were not
statistically distinguishable, it was interesting to compute
the overall statistical analysis in order to estimate the
common biological information extracted by several
instruments and revealing individual metabotypes. The
CCSW analyses also confirmed the partner’s statistical
findings showing at best a tendency to distinguish among
the supplemented versus non supplemented vitamin D rats
(Fig. 2a and online resource Figure 5B).
For both tests, looking at online resource Figure 5, each
sample was represented in the common space (plot) as the
barycentre of all the individual platform results, with the
lines beaming towards the scores of the individual plat-
forms showing their dispersion around the barycentre. In
Test #1, this representation indicated that LCMS presented
less dispersion than NMR in depicting individual metabo-
types (score 2, online resource Figure 5A), whereas NMR
showed less dispersion in extracting intergroup differences
(score 1). This was no longer observed for the low contrast
plasma samples of Test #2 (online resource Figure 5B).
3.2.1 Estimation of the statistical link between instruments
The RV coefficient matrix was calculated on 22 data sets
for Test #1 and on 12 data sets for Test #2. For both tests,
the estimated average links (i.e., RV coefficient) of each
instrument with all of the others are shown in online
resource Fig. 2. RV coefficients can show artificially high
values when comparing megadata sets (Smilde et al. 2009).
We thus compared the observed to the re-sampled RV
values (Online resource Figure 2) and to the modified RV-
coefficient for large datasets designed by Smilde et al.
(2009) (online resource Figure 2). The observed RV values
were generally much higher than the random ones gener-
ated in both tests (online resource Figure 2) and were close
to the modified-RV (online resource Fig. 2), especially in
Test #1.
The RV values can define the convergence between the
instruments in our study, and is thus the ability of each
instrument not to deviate in reporting the individual met-
abolomes in the multivariate space.
In Test #1, the convergence of the metabolic profiles
between instruments was much better than in Test #2. Thus,
the average RV coefficients in Test #1 were close to 0.8
(online resource Figure 2) for all instruments, except for
NMR4 (0.67) and the Orbitrap LCMS O2N operating in
negative mode (0.64). The NMR2 instrument was more
similar to all the LCMS instruments (average RV equal to
0.90) than to the other NMR instruments (average RV equal
to 0.68). To discard the artificial convergence that may arise
from the addition of the standard metabolites, the RV were
recalculated while excluding the spiked urine samples. The
closeness between the instruments based on the RV values
was not modified, as shown in Table 3 and in Fig. 3b.
In Test #2, all instruments had similar levels of con-
cordance (average RV = 0.6), except for the LCMS
instrument O3P (Orbitrap 3 in positive mode), which had
an RV coefficient close to 0.4. This instrument clearly
provided profiling information that did not converge with
the others. Indeed, the distribution of the RV coefficients
based on random re-sampling was close (median = 0.3) to
the original RV coefficient.
When examining the RV coefficients calculated within
methods (e.g., either among NMR or among LCMS), NMR
showed somewhat less convergence in the profiling than
did LCMS in Test #1, irrespective of the artificial contrast
due to spiking (0.78 and 0.77 in NMR versus 0.87 and 0.87
for LCMS in spiked vs non-spiked samples, respectively).
While the same values for Test #1 were found in Test #2
for NMR, the convergence between LCMS was lower in
Test #2 (0.78 for NMR vs. 0.64 for LCMS) (Table 3).
When examining the between methods RV coefficients
(e.g., metabolic profiling convergence between NMR and
LCMS), the values decreased from*0.75 in Test #1 (urine
samples) to 0.54 in Test #2 (rat plasma samples) (Table 3).
Of note is that in Test #1, while QTOF Q6 (both in positive
and negative ionisation modes) was in higher correlation to
NMR than to the other LCMS, the reverse held true for
NMR2, which was in higher correlation to LCMS than to
the other NMR (Table 3). The RV coefficients matrix
(closeness) calculated between each instrument was further
visualised as an interaction network calculated for each test
(Fig. 3). Cut-off values of RV = 0.791 and 0.708 were
chosen in Test #1 and Test #2, respectively, to produce
networks including all nodes with the least number of
edges.
In the Test #1 network, most of the LCMS platforms
clustered together, except for QTOF Q6, which was the
LCMS platform sharing less common information with the
other platforms, irrespective of spiking. Conversely, NMR
N2 tightly clustered with most of the LCMS platforms,
away from the NMR region of the network (Fig. 3a, b).
Noticeably, when data normalisation was performed on the
total area, as with the other NMR, instead of on trimeth-
ylsilyl propionate (TSP), as done originally, the metabolic
profiling of NMR2 looked more like the other NMR than
like the LCMS (online resource Fig. 3). Among the LCMS,
one QTOF (Q2P) and one Orbitrap (O4P) shared the most
common information with all the other instruments. NMR1
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displayed the most ubiquitous information among the NMR
instruments (Figs. 3a, 4b).
In the Test #2 network, LCMS and NMR were also
located in two distinct regions (Fig. 3b). In this test, the
QTOF Q1P and the NMR 4 shared the most common
information with NMR and LCMS, respectively. QTOF
Q4P shared the most common information with the other
LCMS platforms.
Of note, for the LCMS instruments in both tests, the
number of features retained as well as the LCMS tech-
nology (QTOF, TOF or Orbitrap) did not influence the
proximity between instruments (Fig. 3).
3.3 Effect of urine dilution in Test #1
In addition to the obvious differences between the spiked
versus non-spiked urine samples, we addressed whether the
interindividual differences in the metabolic profiling found in
urine could result from variations in urine dilution. For this, a
correction factor was calculated for each non-spiked sample
based on the specific gravity method (Cone et al. 2009)
(Online Table 5). For bothNMRandLCMS, the total spectral
intensity was used to recalculate a new CCSWA model after
correction with the dilution factor (online resource Fig. 3).
This model only emphasised the interindividual metabotype
differences. It showed a very similar pattern of distribution
before and after dilution correction among the individuals for
themain related common components (CC2 panel A andCC1
panel B in Fig. 1 and in online resource Figure 4B, respec-
tively). However, although individuals #5 and #8 were again
identified as outliers, the normalisation of the data to the urine
dilution factor also revealed another heterologous individual
(#2, CC2 of online resource Figure 4, panel A) that was not
previously found. Interestingly, this outlier was mainly
detected by NMR (saliences for CC2, panel B of online
resource Figure 4).
4 Discussion
Our study was designed to evaluate the ability of untar-
geted metabolomics approaches to produce convergent
Table 3 Average RV
coefficients within the NMR
and MS instruments and the
average RV coefficients
between the NMR and MS
instruments for Test #1 and
Test #2
* These instruments are located
in the same platform
a This platform used an
Orbitrap analysis in Test #1 and
a QTOF analysis in Test #2
1 ‘‘Methods’’ refers to NMR
and MS technologies
2 N for NMR spectrometer, Q
for QTOF mass spectrometer, O
for Orbitrap mass spectrometer,
T for TOF mass spectrometer.
The P or N appended to the
mass spectrometer identifier
number denotes positive or
negative ionisation mode,
respectively
3 Calculation made by
excluding the spiked samples
and based only on parent
samples
Instrument2 Within-methods1 RVs Between-methods RVs
Test #1
(n = 25)
Test #13
(n = 25)
Test #2
(n = 18)
Test #1
(n = 25)
Test #13
(n = 25)
Test #2
(n = 18)
NMR
N1 0.86 0.85 0.84 0.74 0.80 0.56
N2 0.68 0.74 – 0.88 0.90 –
N3 0.82 0.79 0.72 0.68 0.70 0.51
N4 0.71 0.63 0.80 0.67 0.60 0.57
N5* 0.85 0.85 0.78 0.72 0.79 0.52
Average 0.78 0.77 0.78 0.74 0.76 0.54
MS
O1P 0.91 0.92 0.68 0.80 0.84 0.56
Q6P/O2Pa 0.76 0.76 0.64 0.88 0.86 0.52
Q6N 0.64 0.66 – 0.73 0.72 –
O3P 0.89 0.90 0.44 0.71 0.74 0.31
O3N 0.91 0.91 0.60 0.70 0.73 0.46
O4P 0.88 0.89 – 0.85 0.85 –
Q1P 0.87 0.87 0.70 0.61 0.65 0.65
Q1N 0.90 0.90 – 0.69 0.71 –
Q2P 0.90 0.90 – 0.85 0.85 –
Q2N 0.88 0.88 – 0.63 0.66 –
Q3P 0.92 0.92 0.67 0.79 0.81 0.55
Q4P 0.91 0.91 0.75 0.72 0.73 0.58
Q4N 0.89 0.91 – 0.67 0.70 –
Q5P* 0.92 0.89 0.66 0.78 0.79 0.66
Q5N* 0.87 0.93 – 0.64 0.67 –
T1P* 0.91 0.87 – 0.79 0.80 –
T1N* 0.90 0.91 – 0.71 0.74 –
Average 0.87 0.87 0.64 0.74 0.75 0.54
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results at the metabolic profiling level when performed on
the same set of samples by instruments of various tech-
nologies and located in different laboratories using non-
standardised procedures. This is to date the largest inter-
laboratory test implemented for metabolomics.
The samples analysed were generated through two
protocols purposely depicting a high and a low biological
contrast situation and extracted from two biofluids, plasma
and urine. These situations and matrices were thought to
reflect the typical analytical metabolomics situations
commonly encountered in human and animal studies.
Although in Test #1 we spiked the samples with known
standards, our main goal was not to make comparisons at
the molecular level but to evaluate the inter-instrument
convergence at the metabolic profiling level, which con-
stitutes the bottom line of untargeted metabolomics.
This approach differed from previous attempts in which
the instruments and/or the analytical conditions were in as
near identical conditions as possible (Ward et al. 2010;
Allwood et al. 2009; Viant et al. 2009; Benton et al. 2012)
or possessed some variations authorised in post-acquisition
procedures (Viant et al. 2009). Our test has the scope to
help us assess to what extent results can be platform
dependent and how trustworthy the findings may be when
obtained under non-standardised conditions using instru-
ments of different technologies.
The samples were analysed on relatively similar NMR
instruments but on rather different LCMS systems, where
the LC varied from conventional to very high pressure, was
from different vendors, and used different chromatographic
columns, ESI conditions, LCMS configurations (TOF,
QTOF, orbital technology) and instrument series (see
online resource). Additionally, specific spectral signal fil-
tering and deconvolution methods were used by each par-
ticipant. As a result of this instrumental, analytical,
acquisition and post-processing heterogeneity, the signal
generated by the various instruments could not be directly
compared on a feature (variable extracted from the work-
flow) basis. Neither could they be compared on a metab-
olite basis, owing to metabolite annotation difficulties and
discrepancies in instrument sensitivity. To circumvent this
difficulty, we implemented spiking experiments in one of
the two tests and also applied two statistical methods that
allowed the comparison of the entire dataset generated by
each platform rather than merely the individual features,
namely, CCSWA and calculation of RV coefficients. The
primary aim of this overall statistical analysis was to assess
the convergence of the metabolic profiling obtained by
Fig. 3 Correlations networks calculated from the pair-wise RV
coefficients matrix from Test #1 (a) with spiked and non-spiked
samples or with native urine samples only (b) and from Test #2 (c).
Node labelling: N NMR platforms, Q QTOF mass spectrometer,
O orbitrap mass spectrometer, T TOF mass spectrometer. The P or N
appended to the mass spectrometer identifier number denotes positive
or negative ionisation mode, respectively. Node shapes: hexagon for
nuclear magnetic resonance platforms, ellipse for mass spectrometers.
The node size is proportional to the number of features retained by
each instrument. The node colour from black to white indicates an
increasing node degree (number of edges per node). The edges
represent the RV coefficient values, with cut off values C0.791 in
Test #1 and C0.708 in Test #2). At this cut off level, O3P was
excluded from the Test #2 network (b)
b
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several types of instruments and depicted as spectral
information, regardless of the metabolite chemistry. In
other words, we investigated how biological status, trans-
lated into metabolomics profiles, could be related when
measured by instruments of various technological designs.
Our results also provided an overview of the number of
features that could be extracted from the same set of
samples compared with those that diverged dramatically
across the platforms, both in Test #1 and Test #2, mainly
due to post-processing methods. This is well highlighted in
Test #1 by the number of discriminating features found by
CCSWA related to the 32 standard molecules (Table 2).
The RV coefficients examining the pair-wise relationships
among the instruments also appeared unaffected by this
factor in both tests, as exemplified in online resource Fig. 2
(average RV) and Fig. 3. Hence, redundancy or parsimony
in the number of features extracted did not seem to com-
promise convergence in the information retrieved across
the platforms. Participants used both PLS-DA models and
VIP scores (Trygg et al. 2007) to select the discriminating
features or used a standard t test. Compared to the selection
made independently from CCSWA, the results were highly
overlapping, indicating the consistency of the discrimi-
nating features isolated across platforms and the statistical
methods used.
Not surprisingly, in the first test matching the native
urine and the urine spiked with the standard mixtures, all
the participants were able to discriminate the two groups
quite clearly. This was not due to any dilution effect owing
to the addition of the spiking solution since we carefully
controlled this factor (see methods section). Of note, the
addition of the standard mixture to the urine samples in
Test #1 did not improve the metabolic profiling conver-
gence (RV values) among either the NMR or the LCMS
results (Table 3). This is likely because the amount of
exogenous metabolites spiking the urines was constant
among all the urine samples and thus did not contribute to
the variation measured across the samples.
When the data were examined for NMR and LCMS
separately, it appeared that, whereas NMR reported steady
‘within’ RV values (0.78) across both tests, this was not the
case for LCMS, for which the RV values were lower in
Test #2 versus Test #1 (Table 3). This cannot be ascribed
to the lower sensitivity of LCMS in the low contrast situ-
ation (Test #2) because the addition of the standard mixture
to the urine (Test #1), which artificially increased the
contrast, did not result in a commensurate convergence
among LCMS (Table 3). In fact, the addition of the stan-
dards did not improve the convergence among the NMR
results, either. Compared to NMR, the lower RV values
observed within LCMS in Test #2 (plasma samples) versus
the RV of the non-spiked urine samples in Test #1 would
suggest a matrix-related effect, in which LCMS was
inferior to NMR in reporting the metabolic profiles in
plasma. This could arise from the trace amount of proteins
that remained in the plasma sample extracts, which would
impair the LCMS analyses. This issue remains to be
carefully addressed.
In Test #2, the vitamin D group could not be clearly
distinguished from the untreated group, but the treated
group displayed the greatest dispersion, suggesting indi-
vidual differences in the treatment response. Additionally,
in Test #2, a tendency for discrimination could be observed
in the common component 2, in which the NMR instru-
ments appeared more influential than did the LCMS
instruments, as indicated by the CC2 scores. The same
pattern also occurred for Test #1, in which the NMRs per-
formed slightly better than the LCMSs in discriminating the
groups (CC1 scores and loadings of Fig. 1). It should be
noted that for sensitivity reasons, the standard concentration
was 10-fold higher in the urine to be analysed by NMR. On
the other hand, the individual metabotypes were more
repeatedly reproduced across the LCMS instruments than
they were in NMR, at least in the Test #1 urine samples
(scores and loadings CC2 in Fig. 1a, b, low dispersion along
the inter-individual CC2 in online resource Figure 5A).
This is further outlined by the better performance of LCMS
in detecting the two outliers in the Test #1 urine and
especially in detecting the blind outlier. For the latter, most
of the LCMS instruments found estroprogestative hormone
derivatives and related steroid hormone derivatives as the
leading discriminating factors, as could be expected
according to the physiological situation of that individual (a
mid-term pregnant woman). NMR did not report similar
discriminating compounds but rather compounds such as
alanine, threonine, lactate, and glycine, which are difficult
to relate specifically to the particular physiological status of
the outlier. This might be due to differences in sensitivity, as
the concentrations of estroprogestative derivatives in
pregnant women are reported to range from 3 to 5 lmol/L
urine (0.5 to 0.8 lg/mL) (Johnson and Williams 2004),
which is within the lowest level or slightly below the limit
of detection for NMR. In addition, possible overlap with
other signals could impair detection. Also likely is that the
compounds found to be discriminating by NMR could be so
for LCMS as well, but to a lesser extent than the estropro-
gestative derivatives primarily detected by LCMS. They
could thus be excluded from the list of the features retained
at the high correlation threshold level chosen (r[ 0.8 for
LCMS). Also interestingly, some laboratories used auto-
mated annotation from METLIN for the XCMS output,
which gave either multiple hits for each m/z feature and/or
irrelevant annotation in the current biological context (see
Q6, O1, and most obviously O4 in online resource Table 4).
This is a good illustration of the care that should be
implemented in post-data acquisition curation.
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For confidentiality reasons, the discriminating metabo-
lites were not investigated for the unexpected outlier.
Interestingly though, LCMS also generally performed
better than did NMR in identifying this individual, except
for one NMR, which similarly pinpointed this individual
(common component 3 of Fig. 1b). This NMR additionally
distinguished itself from the other NMRs by clustering with
LCMS for the other characteristics, such as inter-individual
metabotypes description or group discrimination in Test #1
(common component 2 and common component 1 in
Fig. 1b, respectively). As a result, it also more closely
clustered with all LCMS in the network analysis (Fig. 3a).
The only noticeable difference with the other NMR plat-
forms was that normalisation was performed on trimeth-
ylsilyl propionate (TSP), whereas the other methods used
the total peak area. In general, normalisation is performed
on the total spectral area when dealing with NMR urine
analysis to prevent bias due to the dilution factor varying
widely between urine samples. This is less critical in
plasma due to the much tighter regulation of metabolite
contents. In fact, when NMR2 data were normalised to the
total intensity area as done for the other NMR, its speci-
ficity vanished and it performed closer to the other NMR
for its average RV values, CCSWA scores (except for
individual #8 detection) and RV closeness in network
analysis (online resource Figure 3).
Thus, although obvious differences owing to techno-
logical designs occurred between LCMS and NMR that
may lead to individual metabolite mismatching, the con-
vergence in the spectral characteristics extracted by either
LCMS or NMR was generally satisfactory in our studies
and could even be improved by adjusting the data post-
processing normalisation of an internal standard, such as
TSP. We also assessed whether different data scaling
would affect the results, but found this factor to be irrele-
vant (not shown). Additionally, when focusing on the
LCMS systems, none differed according to whether the
instrument configuration was based on time-of-flight or
orbital design, ionisation mode (positive/negative) or var-
ious LC systems. This result extends to multiple instru-
ments the findings on metabolic profiling made by others
comparing only two mass-analysers (Gika et al. 2010;
Glauser et al. 2013). However, one LCMS Orbitrap (O3)
was somewhat separated from the others in Test #2 when
run in positive mode but not in negative mode. This was
not observed in Test #1, thus indicating a poor contextual
acquisition due to an unidentified and non-constitutive
reason (e.g., source contamination). One instrument (Q6) in
Test #1 was also shifted away from the others, as illustrated
in the network display (Fig. 3a), but this was corrected
when the XCMS parameters were tuned differently and run
on the same original dataset (not shown). With regard to
this post-processing parameter, both the QTOF Q2 and the
Orbitrap O4 operated in positive mode shared the most
common information with all the other platforms in Test
#1, whether LCMS or NMR. O4 in particular, although
similar to O3, used the default XCMS conditions embed-
ded in MetaboAnalyst (http://www.metaboanalyst.ca/) and
displayed somewhat more robust relationships with the
other instruments. Nonetheless, at this stage we cannot
recommend XCMS specific parameters to be tuned to
improve LCMS profiling because a specific design is
required for such an objective (Smith et al. 2006). Of note
is that others found this deconvolution step weakly critical,
even when performed with different software and algo-
rithms (Gu¨rdeniz et al. 2012).
Due to its robustness, the application of untargeted
metabolomics to epidemiological studies has been restric-
ted thus far to NMR (Holmes et al. 2008), although
methods have been implemented for large series for LC–
MS (Dunn et al. 2011). However, these latter could suffer
from mathematical bias. Conversely, LCMS is more sen-
sitive and produced data of higher information density. The
good convergence we found in the spectral information
extracted across LCMS and NMR also indicated that,
although the analytes to be detected may be individually
different, they all described the same biological status. This
is a further illustration that metabotypes are defined over
the whole metabolome, whose constituents are in close
equilibrium. Thus, an interesting strategy to analyse large
sets of samples would be to perform a screening using
NMR to select sub-groups of interest for which the meta-
bolomics coverage could be completed by LCMS.
5 Conclusion
Our primary aim was to assess the disparity of untargeted
metabolomics approaches in characterising the same me-
tabotypes translated into different spectral datasets col-
lected from instruments of various technologies under
unstandardised conditions. Our main finding is that there is
a high convergence in the spectral information produced
from the various instruments to describe the same set of
samples, irrespective of the type of standardisation,
deconvolution method, LCMS analyser or configuration
(QTOF, TOF, Orbitrap delivered by various LC systems,
ionisation modes). The performance of instruments and
methods to identify and match individual metabolites,
especially using LCMS systems (Benton et al. 2012),
remains to be explored in greater depth (such as in http://
www.abrf.org/index.cfm/group.show/MetabolomicsResearch
Group(MPRG).60.htm). Additionally, including GCMS in
such interlaboratory tests for comparison with other analys-
ers appears necessary. At last, our results suggest that data
fusion across platforms using either similar or different
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analytical methodologies and operated with a variety of
experimental settings is possible. Owing to these differences
of experimental settings, high level data fusion relying on
identified metabolites or annotated features should be the
most relevant approach. In this context, sharing common
quality control samples dedicated to a given biological
matrix should permit cross platform normalisation (Dunn
et al. 2011) and could thus be an efficient way to achieve this
goal. Finally, in addition to the analytical convergence, the
absolute validation of untargeted metabolomics in a ring test
would also rely on the convergence of the biological out-
comes arising from the analyses. This remains to be
investigated.
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